Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Clobenpropit dihydrobromide is a potent antagonist and inverse agonist of histamine H3R (histamine H3LR,pEC50 of 8.07)
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 9,000 | |||
5 mg | 在庫あり | ¥ 20,500 | |||
10 mg | 在庫あり | ¥ 35,500 | |||
25 mg | 在庫あり | ¥ 80,000 | |||
50 mg | 在庫あり | ¥ 135,000 | |||
100 mg | 在庫あり | ¥ 192,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 25,000 |
説明 | Clobenpropit dihydrobromide is a potent antagonist and inverse agonist of histamine H3R (histamine H3LR,pEC50 of 8.07) |
ターゲット&IC50 | H2 receptor:5.6 (pKi), H3LR (human):9.44 (pKi), H4 receptor:13 nM (Ki), H3LR (rat):9.75 (pKi) |
In vitro | Clobenpropit inhibited cell migration and increased apoptosis of pancreatic cancer cells in combination with gemcitabine.?Clobenpropit up-regulated E-cadherin, but down-regulated vimentin and matrix metalloproteinase 9 in real-time polymerase chain reaction[1]. |
In vivo | Clobenpropit inhibited tumor growth (gemcitabine 294 46 mg vs combination 154 54 mg, P = 0.02) and enhanced apoptosis in combination with gemcitabine (control 2.5%, gemcitabine 25.8%, clobenpropit 9.7% and combination 40.9%, P = 0.001) by up-regulation of E-cadherin and down-regulation of Zeb1 in Panc-1 xenograft mouse. |
細胞研究 | Pancreatic cancer cells (Panc-1, MiaPaCa-2 and AsPC-1).Concentration: 50 Μm |
分子量 | 470.7 |
分子式 | C14H19Br2ClN4S |
CAS No. | 145231-35-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.71 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Clobenpropit dihydrobromide 145231-35-2 Apoptosis GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor inhibit Clobenpropit histamine H3R antagonist inverse Inhibitor pancreatic agonist cancer H3LR Clobenpropit Dihydrobromide inhibitor